AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01106157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
Trial: NCT01106157
Drug: Pegylated GCSF
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
Trial: NCT01000506
Drug: Placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline every four weeks by i.v.
Trial: NCT01053533
Drug: Chinese herbal medicines plus western therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
Trial: NCT01053533
Drug: western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: supportive therapy and antivirus therapy when necessary
Trial: NCT00209144
Drug: Intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04564456
Drug: ADVAIR DISKUS® 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations Reference product in one study period
Trial: NCT00924001
Drug: DMF5 Melanoma Reactive TIL
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
Trial: NCT00924001
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day x 2 days intravenously
Trial: NCT04858841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo powder once a day in eligible patients
Trial: NCT01352208
Drug: ASP9521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03698474
Drug: Natrium picosulfate / Magnesium citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bowel preparation formula
Trial: NCT03698474
Drug: Polyethylene glycol / Ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bowel preparation formula
Trial: NCT03698474
Drug: Natrium/ Kalium/ Magnesium sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bowel preparation formula
Trial: NCT02994927
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally or intravenously administered
Trial: NCT02994485
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
Trial: NCT01735383
Drug: Etodolac Tablets USP 500mg
RxNorm normalized name: etodolac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT00441844
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00159640
Drug: PD-217,014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01735383
Drug: Etodolac Tablets USP 500 mg
RxNorm normalized name: etodolac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet once a day
Trial: NCT03183752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg placebo three times daily
Trial: NCT01194219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical matching placebo
Trial: NCT01194219
Drug: Topical treatments or phototherapy
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
Trial: NCT00048607
Drug: Comparator: Placebo (Unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00781443
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating subcutaneous injection
Trial: NCT03125980
Drug: capecitabine plus oxaliplatin after surgery
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W
Trial: NCT02630069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500mg once a day for 12 weeks
Trial: NCT04598269
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical solution containing no ATI-1777
Trial: NCT01927055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match droxidopa capsules and strength designations
Trial: NCT04365933
Drug: EYP001a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01154621
Drug: AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
Trial: NCT01154621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 5% dextrose solution
Trial: NCT01888796
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03608514
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
Trial: NCT03375021
Drug: CX717 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX717 200 mg capsules BID
Trial: NCT03375021
Drug: CX717 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX717 4 X 200 mg capsules BID
Trial: NCT03375021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 200 mg or 800 mg capsules BID
Trial: NCT02935608
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01564823
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine: 2.5 mg/kg of weight/day. 3 months.
Trial: NCT02840279
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
Trial: NCT02840279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01484652
Drug: COV795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets taken every 12 hours
Trial: NCT01484652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets taken every 12 hours
Trial: NCT02935608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02337907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for blinding purposes
Trial: NCT02337907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02838056
Drug: epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
Trial: NCT01152788
Drug: rIL-21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
Trial: NCT00783601
Drug: Comparator: MK0524 + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
Trial: NCT00783601
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
Trial: NCT02184065
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04301323
Drug: BHVI1 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including 35 children enrolled to receive BHVI1 eye-drops once nightly
Trial: NCT04301323
Drug: BHVI2 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including 35 children enrolled to receive BHVI2 eye-drops once nightly
Trial: NCT00791518
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention
Trial: NCT04301323
Drug: BHVI3 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
Trial: NCT00171223
Drug: STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI571 oral capsules or tablets.
Trial: NCT00149123
Drug: hydrocortisone 200 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02994927
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally administered
Trial: NCT03171987
Drug: Flurbiprofen patch local application
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.
Trial: NCT00071760
Drug: GW433908
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamprenavir suspension bid
Trial: NCT01096810
Drug: TBL 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
Trial: NCT02914652
Drug: Norflouran (Placebo Evohaler(R) )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
Trial: NCT04434365
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins once daily for 12±1 weeks.
Trial: NCT01075698
Drug: Non-ARB (standard therapy)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering therapy except ARB
Trial: NCT01075698
Drug: ARB (Telmisartan)
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 20-80 mg/day
Trial: NCT00174655
Drug: Doxorubicine + docetaxel sequential
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
Trial: NCT00174655
Drug: doxorubicine + cyclophosphamide sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
Trial: NCT00174655
Drug: doxorubicine + cyclophosphamide combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Trial: NCT00174655
Drug: doxorubicine + docetaxel combined
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
Trial: NCT04407312
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablet, 200mg, once daily, 30 days.
Trial: NCT01265849
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Trial: NCT01265849
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
Trial: NCT00185302
Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
Trial: NCT00185302
Drug: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
Trial: NCT01309789
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV every 3 weeks (Cycles 3-8)
Trial: NCT01309789
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV every 3 weeks (Cycles 1-6)
Trial: NCT01309789
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV every 3 weeks (Cycles 3-8)
Trial: NCT01309789
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV every 3 weeks (Cycles 1-6)
Trial: NCT00853892
Drug: OxyContin® 40 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxyContin® 40 mg tablet, single dose fasting
Trial: NCT01476410
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04003844
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coadministration
Trial: NCT00506454
Drug: Lipidose
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
Trial: NCT00506454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
Trial: NCT01930604
Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04475107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01001611
Drug: CKD-501 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
Trial: NCT01001611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
Trial: NCT00335972
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
Trial: NCT03884348
Drug: proton pump inhibitor, amoxicillin, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
Trial: NCT02110342
Drug: [14C] PF-04449913
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
Trial: NCT01741181
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
Trial: NCT01741493
Drug: ABT-494
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of ABT-494 capsules
Trial: NCT01741493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo capsules
Trial: NCT04288856
Drug: BIIB078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02469454
Drug: conventional insertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
Trial: NCT03984591
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone according to guidelines
Trial: NCT03984591
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone according to guidelines
Trial: NCT02484963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02802592
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
Trial: NCT01547000
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered up to 8 weeks.
Trial: NCT00276406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Trial: NCT02220933
Drug: MD1003 100mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02220933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867451
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
Trial: NCT03909412
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
Trial: NCT02882854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
Trial: NCT02649920
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01127633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
Trial: NCT01248442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00374881
Drug: Sorbitol+Phenylephrine
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol+Phenylephrine
Trial: NCT00374881
Drug: Sorbitol+Phenylephrine+Morphine
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol+Phenylephrine+Morphine
Trial: NCT00374881
Drug: Sorbitol low concentration+Phenylephrine+Morphine
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol low concentration+Phenylephrine+Morphine
Trial: NCT00688467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
Trial: NCT03497273
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
Trial: NCT00852579
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose 250mg